HarNeedi - Healthcare & Pharma Job Portal

TECHNOLOGY ENHANCING VACCINE EFFICIENCY: It is a well known fact that, for any pharma companies the most crucial and challenging issue is inventing a technology that can enhance the activity of vaccines. A paper published in Journal vaccine, 2008, by a company called Cure Lab, Inc. a Massachusetts based biotechnology company developed a new methodology for anti-viral vaccination. This vaccination technology comprises of two main components: The 1st component comprises of vaccine antigen that should be in two patterns. One should be easily processed inside the organism’s cells by an intracellular “chopping machine” called proteosome, while other element is resistant to “chopping”. According to the research published in Journal Vaccine, both these forms of an antigen would be used in combination to elicit a much stronger immune response than either of them would be able to do alone. With the invention of technology that could create a form of viral protein that could be eas...

Very frequently we will be seeing that, someone in a biopharma company will say “it’s time to think about GMP training”. This statement will generally be received with little exuberance from those who get to know however even so a plan will be in place to conduct GMP training over the next 4 or 5 months or so. On the training day the majority of the resources will present with evenly low levels of enthusiasm as the GMP session begins. “Well let’s start” the GMP trainer will say, as the participants think “well let’s get this over and done with” as they pay close attention to the focus area of this time training – which is generally what they did so poorly wrongly last time! In point of fact, the same could be conveyed for most training departments. They covetously guard their turf and present average, cursory training. Now this might not be incisively what happens in your company however some components of the above are the correct. This does implore some really import...